We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy.
- Authors
Godano, Elisabetta; Barra, Fabio; Allodi, Alessandra; Ferraiolo, Antonella; Laroni, Alice; Novi, Giovanni; Mancardi, Giovanni Luigi; Gustavino, Claudio; Arioni, Cesare
- Abstract
Background: Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women with highly active disease who plan a pregnancy or have an unplanned pregnancy, after accurate counseling about eventual maternal disease relapse due to therapy suspension. Case presentation: This brief case report describes a case of documented anemia that we observed in a newborn whose mother with relapsing-remitting multiple sclerosis was treated with an extended dosing protocol of natalizumab throughout pregnancy. The newborn received the infusion of erythropoietin every seven days from the fortieth day of life; subsequently, the status of anemia underwent clinical resolution. Conclusions: This case report confirmed that natalizumab can cause disorders of hematopoiesis, including anemia, thrombocytopenia, or pancytopenia, in newborns of patients treated during pregnancy. A multidisciplinary team, including experienced pediatricians and pediatric hematologists, has a critical role in managing newborns delivered by women, being treated with natalizumab for treating relapsing-remitting multiple sclerosis during pregnancy.
- Subjects
MULTIPLE sclerosis; NEONATAL anemia; NATALIZUMAB; ERYTHROPOIETIN; PREGNANCY
- Publication
Italian Journal of Pediatrics, 2021, Vol 47, Issue 1, p1
- ISSN
1720-8424
- Publication type
Article
- DOI
10.1186/s13052-021-01025-4